Scribe expects to initiate a first-in-human hypercholesterolemia study in mid-2026 with STX-1150, its lead cardiometabolic assetSTX-1150 is designed to deliver durable therapeutic LDL-C lowering with ...
1h
Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas
Parse Biosciences and Graph Therapeutics to create one of the largest and most comprehensive immune cell perturbation atlases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback